Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
1056901-62-2
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
2 substrates of this enzyme
It does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 ~20-100 µM)
10074-G5 - CAS# 413611-93-5 60423 Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens10074 G5, CAS No. 413611 93 5, is a c Myc Max interaction inhibitor. 10074 G5, similarly to 10058 F4 (#F3680), specifically inhibits this interaction by binding to c Myc, thus preventing C Myc specific DNA binding and target genes regulation. Product information CAS Number: 413611 93 5 Molecular Weight: 332. 31 Formula: C18H12N4O3 Synonym: 10074 G5 10074G5 4 nitro N (2 phenylphenyl) 2,1,3 benzoxadiazol 7 amine N 2 Biphenylyl 7 nitro 2,1,3
US$ 35.96
US$ 26.96
US$ 195.00
US$ 52.00
US$ 17.20